List of BioCryst Pharmaceuticals patents

Patents where

Current Assignee

Name

BioCryst Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 8242085 Tetrahydrofuro [3,4-D] dioxolane compounds for use in the treatment of viral infections and cancer	Patent 8242085 was granted and assigned to BioCryst Pharmaceuticals on August, 2012 by the United States Patent and Trademark Office.		BioCryst Pharmaceuticals	United States Patent and Trademark Office	8242085	August 14, 2012
‌ US Patent 8440813 Antiviral nucleoside analogs	Patent 8440813 was granted and assigned to BioCryst Pharmaceuticals on May, 2013 by the United States Patent and Trademark Office.		BioCryst Pharmaceuticals	United States Patent and Trademark Office	8440813	May 14, 2013
‌ US Patent 8133870 Therapeutic furopyrimidines and thienopyrimidines	Patent 8133870 was granted and assigned to BioCryst Pharmaceuticals on March, 2012 by the United States Patent and Trademark Office.		BioCryst Pharmaceuticals	United States Patent and Trademark Office	8133870	March 13, 2012
‌ US Patent 11021458 Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors	Patent 11021458 was granted and assigned to BioCryst Pharmaceuticals on June, 2021 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	11021458	June 1, 2021
‌ US Patent 7994139 Antiviral therapeutic agents	Patent 7994139 was granted and assigned to BioCryst Pharmaceuticals on August, 2011 by the United States Patent and Trademark Office.		BioCryst Pharmaceuticals	United States Patent and Trademark Office	7994139	August 9, 2011
‌ US Patent 11866418 Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors	Patent 11866418 was granted and assigned to BioCryst Pharmaceuticals on January, 2024 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	11866418	January 9, 2024
‌ US Patent 10329260 Human plasma kallikrein inhibitors	Patent 10329260 was granted and assigned to BioCryst Pharmaceuticals on June, 2019 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	10329260	June 25, 2019
‌ US Patent 11370774 Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors	Patent 11370774 was granted and assigned to BioCryst Pharmaceuticals on June, 2022 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	11370774	June 28, 2022
‌ US Patent 11230530 Human plasma kallikrein inhibitors	Patent 11230530 was granted and assigned to BioCryst Pharmaceuticals on January, 2022 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	11230530	January 25, 2022
‌ US Patent 11559515 Indole compounds and analogues thereof	Patent 11559515 was granted and assigned to BioCryst Pharmaceuticals on January, 2023 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	11559515	January 24, 2023
‌ US Patent 11464755 Antiviral treatments		BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	11464755	October 11, 2022
‌ US Patent 11203574 Human plasma kallikrein inhibitors	Patent 11203574 was granted and assigned to BioCryst Pharmaceuticals on December, 2021 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	11203574	December 21, 2021
‌ US Patent 11192861 Human plasma kallikrein inhibitors	Patent 11192861 was granted and assigned to BioCryst Pharmaceuticals on December, 2021 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	11192861	December 7, 2021
‌ US Patent 11685721 Human plasma kallikrein inhibitors	Patent 11685721 was granted and assigned to BioCryst Pharmaceuticals on June, 2023 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	11685721	June 27, 2023
‌ US Patent 10125102 Human plasma kallikrein inhibitors	Patent 10125102 was granted and assigned to BioCryst Pharmaceuticals on November, 2018 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	10125102	November 13, 2018
‌ US Patent 11708332 Human plasma kallikrein inhibitors	Patent 11708332 was granted and assigned to BioCryst Pharmaceuticals on July, 2023 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	11708332	July 25, 2023
‌ US Patent 11661426 Imidazole-containing inhibitors of ALK2 kinase	Patent 11661426 was granted and assigned to BioCryst Pharmaceuticals on May, 2023 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	11661426	May 30, 2023
‌ US Patent 11708333 Human plasma kallikrein inhibitors	Patent 11708333 was granted and assigned to BioCryst Pharmaceuticals on July, 2023 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	11708333	July 25, 2023
‌ US Patent 11618733 Crystalline salts of a plasma kallikrein inhibitor	Patent 11618733 was granted and assigned to BioCryst Pharmaceuticals on April, 2023 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	11618733	April 4, 2023
‌ US Patent 10662160 Crystalline salts of a plasma kallikrein inhibitor	Patent 10662160 was granted and assigned to BioCryst Pharmaceuticals on May, 2020 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	10662160	May 26, 2020
‌ US Patent 11708347 Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors	Patent 11708347 was granted and assigned to BioCryst Pharmaceuticals on July, 2023 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	11708347	July 25, 2023
‌ US Patent 9770427 Antiviral treatments	Patent 9770427 was granted and assigned to BioCryst Pharmaceuticals on September, 2017 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	9770427	September 26, 2017
‌ US Patent 10562850 Human plasma kallikrein inhibitors	Patent 10562850 was granted and assigned to BioCryst Pharmaceuticals on February, 2020 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	10562850	February 18, 2020
‌ US Patent 9499554 Anti-influenza compositions and methods	Patent 9499554 was granted and assigned to BioCryst Pharmaceuticals on November, 2016 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	9499554	November 22, 2016
‌ US Patent 10633345 Human plasma kallikrein inhibitors	Patent 10633345 was granted and assigned to BioCryst Pharmaceuticals on April, 2020 by the United States Patent and Trademark Office.	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals	United States Patent and Trademark Office	10633345	April 28, 2020

Results per page:

49 results

0 selected

49 results

0 selected